相关实验视频
Updated: Jul 25, 2025

06:41
Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
Published on: October 24, 2018
12.5K
外体膜氧化对严重冠状病毒病毒中宿主转录基因反应的影响
Deane E Smith1, Chandra M Goparaju1, Harvey I Pass1
1Department of Cardiothoracic Surgery, NYU Langone Health, New York, New York.
Annals of thoracic surgery short reports
|June 26, 2023
概括
身体外膜氧化 (ECMO) 在重症COVID-19患者中暂时改变免疫系统. 这项研究揭示了在ECMO治疗期间和之后免疫基因表达的显著变化.
科学领域:
- 免疫学 免疫学 免疫学
- 关键护理医学 关键护理医学
- 基因组学就是基因组学.
背景情况:
- 重症COVID-19患者表现出免疫失调,导致器官损伤.
- 身体外膜氧化 (ECMO) 在严重的COVID-19病例中使用,结果可变.
- 在COVID-19中ECMO对宿主免疫反应的影响需要进一步阐明.
研究的目的:
- 为了研究ECMO对重症COVID-19患者免疫转录组特征的影响.
- 分析ECMO治疗期间与免疫路径相关的细胞因子水平和基因表达的变化.
主要方法:
- 研究了接受ECMO治疗的11名COVID-19重症患者.
- 在三个时间点评估细胞因子水平和外围白细胞免疫转录组:在ECMO之前,启动后24小时,解禁后2小时.
- 多重细胞因子面板和NanoString nCounter技术用于分析.
主要成果:
- 在ECMO前和ECMO后24小时样本之间观察到11个宿主免疫基因的显著差异性基因表达.
- 参与收费类受体信号传递的MD2和MRC1显示出最显著的变化.
- 反应体通路分析表明,对关键的炎症通路有很大影响.
结论:
- 在严重的COVID-19中,ECMO治疗对宿主免疫转录组反应有明显的时间效应.
- 了解这些免疫变化可能会为ECMO支持患者的未来治疗策略提供信息.
相关概念视频
Acute Respiratory Failure-II
285
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
285
Acute Respiratory Failure-V
169
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
169
Acute Respiratory Failure-I
253
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
253
Acute Respiratory Failure-III
232
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
232
Pneumonia II: Pathophysiology
362
The pathophysiology of pneumonia involves the following steps:
362
Acute Respiratory Failure-IV
179
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
179

